aTYR PHARMA INC — Director's Dealing 2023

Apr 28, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2023-04-26

Reporting Person: CLARKE JOHN K (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-26	Common Stock	M	6000	—	Acquired	19797	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-26	Restricted Stock Unit	$	M	6000	Disposed		Common Stock (0)	Direct

Footnotes

F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022.

F2: RSUs convert into common stock on a one-for-one basis.

F3: Includes 6,305 shares received as a pro-rata distribution on September 28, 2021 (the "Liquidating Distribution") from CHP II, L.P., in which the Reporting Person is a managing partner. In prior reports, the reporting person reported beneficial ownership of 108,083 shares of aTyr Pharma common stock held by CHP II, L.P., which are no longer held as of September 28, 2021 due to the Liquidating Distribution.

F4: The RSUs fully vested one year from the grant date which was April 26, 2022.